Shopping Cart
- Remove All
- Your shopping cart is currently empty
YHO-13351 is an ABCG2 inhibitor, an acrylonitrile derivative, that induces sensitization of cancer stem/initiating-like side population cells to irinotecan.GSK1702934A can be used to study diabetes.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $30 | In Stock | |
5 mg | $64 | In Stock | |
10 mg | $106 | In Stock | |
25 mg | $176 | In Stock |
Description | YHO-13351 is an ABCG2 inhibitor, an acrylonitrile derivative, that induces sensitization of cancer stem/initiating-like side population cells to irinotecan.GSK1702934A can be used to study diabetes. |
In vitro | In the presence of YHO-13351 (0-0.1 μM), HeLa cells stained with Hoechst dye were analyzed by flow cytometry using a fluorescence-activated cell sorter, which revealed that YHO-13177 is capable of reducing the SP fraction score [2]. |
In vivo | When used in combination with irinotecan, YHO-13351 reduces the increase in the ratio of SP cells in tumors compared to treatment with irinotecan alone[2]. |
Alias | YHO13351, YHO 13351 |
Molecular Weight | 579.73 |
Formula | C27H37N3O7S2 |
Cas No. | 1346753-00-1 |
Smiles | S(C)(=O)(=O)O.C(=C(\C#N)/C1=CC(OC)=C(OC)C=C1)\C=2SC(=CC2)N3CCC(OC(CN(CC)CC)=O)CC3 |
Relative Density. | no data available |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 160 mg/mL (276.00 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.